Evidence map›Paper›PMID 36438710›Full record

ArticleWorld journal of gastrointestinal oncology2022

KLF16 promotes pancreatic adenocarcinoma cell proliferation and migration by positively regulating SMAD6.

Wei Mi, Zhi Zheng, Jiong-Di Lu, Shu-Quan Duan, Jie Zhang, Hai-Qiao Zhang, Yi-Xuan Ding, Jie Yin, Feng Cao, Jun Zhang and 1 more

Open access · diamondAbstract read
In one paragraph

Article in World journal of gastrointestinal oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A novel and independent survival prognostic model for OSCC: the functions and prognostic values of RNA-binding proteins.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Wei MiDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Zhi ZhengDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Jiong-Di LuDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Shu-Quan DuanDepartment of Digestive Minimally Invasive Surgery, The Second Affiliated Hospital of Baotou Medical College, Baotou 014030, Inner Mongolia Autonomous Region, China.
Jie ZhangDepartment of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Hai-Qiao ZhangDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Yi-Xuan DingDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Jie YinDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Feng CaoDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Jun ZhangDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China. zhangjun5986@ccmu.edu.cn.
Fei LiDepartment of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Capital Medical University · CNBeijing Friendship Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic adenocarcinoma (PAAD) is a cancerous tumor with an extremely poor 5-year survival rate. The exploration of biomarkers for the diagnosis and treatment of PAAD is crucial in clinical practice. Krüppel-like factors (KLFs) are involved in a variety of biological functions in cells. According to multiple studies, KLF16 behave as an oncogene in prostate, breast and gastric cancers. However, no research has been done on the significance of KLF16 in PAAD.

aimTo explore the molecular mechanisms of KLF16 in PAAD.

methodsKLF16 was identified in the tumor specimens and normal tissues by GEPIA database and verified by quantitative real-time PCR (qRT-PCR). Knockdown or exogenous expression of KLF16, combined with

resultsWe showed that KLF16 was highly expressed in PAAD patients based on the GEPIA database. KLF16 silencing suppressed while KLF16 overexpression promoted the malignant function of PAAD cells. Based on RNA sequencing, we discovered that KLF16 potentiated the expression of SMAD6 in PAAD cells. SMAD6 transcript abundance was increased and positively correlated with KLF16 expression in PAAD samples. In addition, inhibiting SMAD6 was able to mitigate the effects of KLF16 overexpression on PAAD cell processes, suggesting the importance of SMAD6 in the development of KLF16-triggered PAAD.

conclusionKLF16/SMAD6 axis might be explored as a therapeutic target for PAAD therapy.

Indexed as

KLF16Pancreatic adenocarcinomaSMAD6Therapeutic targetTumorigenesis

Identifiers

PMID36438710
PMCPMC9694270
OpenAlexW4309011369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.